Skip to main content
Lobe Sciences Ltd. logo

Lobe Sciences Ltd. — Investor Relations & Filings

Ticker · LOBE CSE Manufacturing
Open in API
Filings indexed 206 across all filing types
Latest filing 2025-12-30 Regulatory Filings
Country CA Canada
Listing CSE LOBE

About Lobe Sciences Ltd.

https://www.lobesciences.com/

Lobe Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for rare and underserved diseases with unmet medical needs. The company utilizes innovative technologies, including lipid technology, to advance its pipeline. Through its subsidiary, Cynaptec Pharmaceuticals, Lobe is developing L-130 (Conjugated Psilocin™), a patented formulation engineered to provide the therapeutic effects of psilocybin without the hallucinogenic properties. Its second subsidiary, Altemia, Inc., develops S-100, a novel medical food product intended for the dietary management and treatment of Sickle Cell Disease. The company's research targets conditions such as Chronic Cluster Headache and Sickle Cell Disease.

Recent filings

Filing Released Lang Actions
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a Form 13-502F1, which is a regulatory filing required by the Ontario Securities Commission (OSC) for reporting issuers to calculate and pay their annual participation fees. It is not an annual report, earnings release, or any other specific corporate communication listed in the categories. As it is a standard regulatory compliance form submitted to a securities commission, it falls under the 'Regulatory Filings' (RNS) category.
2025-12-30 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a Form 13-501F1, which is a regulatory filing used by reporting issuers in Canada (specifically Alberta) to calculate and report their participation fees based on market capitalization. It is a standard regulatory compliance document submitted to a securities commission. Since it does not fit into categories like financial reports, earnings releases, or shareholder communications, it falls under the general regulatory filings category.
2025-12-30 English
52-109F1 - Certification of annual filings - CEO (E).pdf
Audit Report / Information Classification · 1% confidence The document is a 'Form 52-109FV1', which is a Venture Issuer Basic Certificate required under Canadian securities legislation to accompany annual filings. It serves as a formal certification of the accuracy and fair presentation of the company's annual financial statements and MD&A. Since it is a standalone regulatory certification document rather than the annual report itself, and it does not fit into the other specific categories like 'Audit Report' or 'Management Report', it is best classified as a Regulatory Filing. FY 2025
2025-12-30 English
52-109F1 - Certification of annual filings - CFO (E).pdf
Audit Report / Information Classification · 1% confidence The document is a 'Form 52-109FV1', which is a Venture Issuer Basic Certificate required under Canadian securities legislation. This form serves as a formal certification by the CEO and CFO regarding the accuracy and fair presentation of the company's annual filings (financial statements and MD&A). Since this is a regulatory certification document that accompanies the annual reporting package rather than the annual report itself, and it does not fit into the other specific categories like '10-K' or 'AR' (which are the reports themselves), it is best classified as a Regulatory Filing. FY 2025
2025-12-30 English
Annual MD&A - English.pdf
Management Reports Classification · 1% confidence The document is explicitly titled 'Management’s Discussion & Analysis' (MD&A) for Lobe Sciences Ltd. for the years ended August 31, 2025 and 2024. It provides a detailed narrative explanation of the company's financial condition, results of operations, business overview, and forward-looking statements. This content aligns perfectly with the definition of a Management's Discussion & Analysis report, which is a core component of financial reporting.
2025-12-30 English
Audited annual financial statements – English.pdf
Annual Report Classification · 1% confidence The document is a comprehensive set of 'Consolidated Financial Statements' for Lobe Sciences Ltd. for the years ended August 31, 2025 and 2024. It includes an Independent Auditor's Report, Consolidated Statements of Financial Position, Consolidated Statements of Loss and Comprehensive Loss, and Consolidated Statements of Cash Flows. This constitutes a full annual financial report, which falls under the 10-K category for annual reporting purposes. FY 2025
2025-12-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.